Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2014-10-27 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Share Purchase Plan extended to 28 November 2014 2 pages 50.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the extension of the closing date for a Share Purchase Plan. It discusses regulatory compliance with ASIC Class Order CO 09/425 and the market price conditions for the share issue. There is no financial data, no detailed report, no management discussion, or earnings information. The document is a specific update on a capital raising activity (share purchase plan extension). This fits the category of Capital/Financing Update (CAP). The document length is 4838 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2014-10-27 English
Appendix 4C 30 Sep 2014 7 pages 99.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 September 2014' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It references the quarter ended 30 September 2014, indicating it is a quarterly financial report. The content includes actual financial data such as cash flows, payments to directors, and reconciliation of cash balances. The document is over 12,000 characters, indicating it is a full report rather than a brief announcement. The Appendix 4C is a standard quarterly cash flow report for entities admitted on the basis of commitments, commonly used in Australian stock exchange filings. This matches the definition of an Interim / Quarterly Report (IR), which must contain substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2015
2014-10-27 English
Annual Report to shareholders 48 pages 1.4MB
Annual Report Classification · 100% confidence The document is titled '2013 - 2014 Annual Report' and contains detailed sections typical of an annual report, including Chairman's report, CEO's report, Directors' report, Auditor's independence declaration, Corporate governance statement, and comprehensive financial statements such as consolidated statement of profit or loss, financial position, changes in equity, cash flows, notes to financial statements, directors' declaration, and independent auditor's report. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes detailed business overview, strategic updates, clinical trial progress, financial position, and governance information, all consistent with a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2014
2014-10-16 English
Notice of Annual General Meeting/Proxy Form 8 pages 354.0KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and details the agenda for the AGM of Living Cell Technologies Limited, including resolutions to be voted on such as adoption of the remuneration report, re-election of directors, and ratification of share issues. It includes explanatory notes for shareholders and proxy voting instructions. The document does not contain the actual financial report or detailed financial statements but refers shareholders to the Annual Report available on the company's website. The content is consistent with a notice or invitation to an AGM rather than the full Annual Report or other filings. Therefore, the document is best classified as AGM Information (AGM-R).
2014-10-16 English
Share Purchase Plan Offer Terms and Conditions 10 pages 483.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'SHARE PURCHASE PLAN OFFER TERMS AND CONDITIONS' and details the terms, eligibility, offer price, application process, and other conditions related to a share purchase plan (SPP) by Living Cell Technologies Limited. It includes specific dates for the offer period, instructions for shareholders, and legal disclaimers. There is no financial statement, earnings data, or management discussion of financial results. The document is a formal offer to shareholders to purchase additional shares under specified terms, which is a capital raising activity. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2014-10-14 English
Change in substantial holding 3 pages 99.8KB
Regulatory Filings
2014-10-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.